VSTM Verastem Inc.

+0.16  (+5%)
Previous Close 3.29
Open 3.31
Price To Book 2.36
Market Cap 254580137
Shares 73,791,344
Volume 1,997,428
Short Ratio
Av. Daily Volume 2,359,677

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 presentation ASCO June 2018.
Peripheral T-Cell Lymphoma (PTCL)
Phase 1/2 initiation of dosing announced January 26, 2017.
Avelumab and defactinib
Ovarian cancer
Phase 1/2 initial data - 21st Congress of European Hematology Association June 9 - 12, 2016
Duvelisib - Conetempo
Treatment-naïve patients with follicular lymphoma
Phase 2 data released June 2016 - short of expectations
Duvelisib (IPI-145) DYNAMO
Indolent non-Hodgkin lymphoma
FDA Approval announced September 24, 2018.
Duvelisib - DUO
Chronic lymphocytic leukemia (CLL)//Small Lymphocytic Lymphoma (SLL)/Follicular Lymphoma
Phase 2 interim analysis showed lack of efficacy. Trial stopped. September 2015
Mesothelioma prior to surgery
Phase 2 failed to meet endpoint - Jan 2015
Duvelisib (IPI-145)
Rheumatoid arthritis

Latest News

  1. Here's Why Verastem Tumbled 34.1% in December
  2. 4 Healthcare Stocks Looking To Set January Highs
  3. Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  4. The Daily Biotech Pulse: Novavax Reports Positive Influenza Vaccine Trial Data, Flexion Warns Of Revenue Shortfall, Retrophin's New CEO
  5. New Research: Key Drivers of Growth for The Blackstone Group, Barnes & Noble, Verastem, Littelfuse, Essendant, and Anworth Mortgage Asset — Factors of Influence, Major Initiatives and Sustained Production
  6. Verastem Oncology Outlines Strategic Priorities for 2019 and Highlights Recent Progress
  7. Verastem Oncology to Present at the 37th Annual J.P. Morgan Healthcare Conference
  8. Hedge Funds Are Crazy About Verastem Inc (VSTM)
  9. Have Insiders Been Buying Verastem, Inc. (NASDAQ:VSTM) Shares This Year?
  10. Verastem Oncology Added to the NASDAQ Biotechnology Index®
  11. Verastem Oncology Announces First Recipient of the Care Differently Award for Excellence in Patient Support and Education
  12. Verastem Oncology Presents Duvelisib Development Program Data at the American Society of Hematology 2018 Annual Meeting
  13. Verastem Oncology Announces Presentation of Updated Duvelisib Combination Clinical Data in Peripheral T-Cell Lymphoma at the American Society of Hematology 2018 Annual Meeting
  14. Is Verastem (VSTM) Stock Outpacing Its Medical Peers This Year?
  15. Verastem Oncology Reports Third Quarter 2018 Financial Results
  16. Verastem Oncology Announces Collaboration with The Leukemia & Lymphoma Society to Accelerate Development of Duvelisib for the Treatment of Peripheral T-Cell Lymphoma
  17. Verastem Oncology Announces Presentation of Preclinical Data Supporting Dual PI3K-delta and PI3K-gamma Inhibition in Combination with Immunotherapy at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting